Quercetin as a multi-targeted therapeutic candidate in oral cancers: molecular mechanisms and preclinical evidence

Qamar Abuhassan1, Omer Qutaiba B Allela2, Wadhah Hasan Alkhazali3

  • 1Department of Pharmaceutics and Pharmaceutical Technology, School of Pharmacy, University of Jordan, Amman, 11942, Jordan.

Insights

Quercetin, a natural flavonoid, shows significant anticancer effects against oral squamous cell carcinoma (OSCC) by inducing apoptosis and inhibiting cancer cell growth and spread. Further research is needed to overcome its poor bioavailability for clinical use.

Area of Science:

  • Oncology
  • Natural Products Chemistry
  • Molecular Biology

Background:

  • Oral squamous cell carcinoma (OSCC) presents significant challenges in treatment, with high recurrence rates and suboptimal survival.
  • Novel therapeutic strategies are crucial to improve outcomes for patients with oral malignancies.
  • Quercetin, a dietary flavonoid, exhibits promising antioxidant, anti-inflammatory, and anticancer properties relevant to oral cancer.

Purpose of the Study:

  • To review the current evidence on quercetin's anticancer effects in oral malignancies.
  • To elucidate the molecular mechanisms underlying quercetin's therapeutic potential against oral cancer.
  • To highlight challenges and future directions for clinical translation of quercetin.

Main Methods:

  • In vitro studies assessing quercetin's effects on oral cancer cell viability, proliferation, and apoptosis.
  • Analysis of cell-cycle regulation, intrinsic and extrinsic apoptotic pathways, and epithelial-mesenchymal transition (EMT) markers.
  • In vivo studies evaluating tumor growth and systemic toxicity.

Main Results:

  • Quercetin significantly reduced oral cancer cell viability, proliferation, and clonogenic potential.
  • Apoptosis was induced via both intrinsic (ROS, mitochondria, caspases) and extrinsic (Fas/Fas-L, caspase-8) pathways.
  • Quercetin inhibited migration, invasion, EMT, angiogenesis (VEGF), and matrix degradation (MMP-2, MMP-9).
  • In vivo studies showed reduced tumor volume and growth without significant toxicity.

Conclusions:

  • Quercetin demonstrates multi-targeted anticancer potential against oral malignancies through various molecular mechanisms.
  • Its efficacy in vitro and in vivo suggests therapeutic promise for oral cancer.
  • Poor bioavailability and rapid metabolism are key limitations for clinical application, necessitating optimized delivery systems and clinical trials.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...